Q-omics provides the consensus-scored LRRIQ3 profile across patient tissues and cancer cell-line models. LRRIQ3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LRRIQ3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LRRIQ3 RNA expression shows 17,886 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where LRRIQ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRIQ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRIQ3 survival associations across molecular data types. LRRIQ3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRIQ3 RNA expression–survival associations across cancer types. High LRRIQ3 expression shows unfavorable associations in THCA, LIHC and LGG, but favorable associations in BRCA, MESO and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LRRIQ3 RNA expression.
This table summarizes LRRIQ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRIQ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRIQ3 shows lower tumor expression in KICH, THCA, KIRC and KIRP and higher tumor expression in BLCA and STAD. The KICH box plot shows higher LRRIQ3 RNA expression in normal versus tumor tissue (log2 FC = −0.944, t-test p < 0.001).
This table shows molecular features associated with LRRIQ3 in patient tissues and cancer cell lines. In patient samples, LRRIQ3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRIQ3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
